The Cheating Problem

An elephant has many times more cells than a human and lives long enough for those cells to accumulate decades of mutations. Elephants should be riddled with cancer. They are not. Their cancer mortality rate is about 5 percent. Ours is 11 to 25 percent. The observation that large, long-lived animals should drown in cancer but do not is called Peto's Paradox, named for the Oxford statistician Richard Peto, who first formulated the problem in the 1970s.

The paradox begins to resolve when you shift attention from mutations to the systems that manage them. Elephants do not get less cancer because they mutate less. They get less cancer because they evolved stacked constraints that absorb mutations before they matter.

Cancer is not fundamentally about mutations. It is about the layered systems that detect, constrain, and eliminate would-be defectors. Illness happens when enough of those layers erode.

The View from Inside

In the hospital, I started reading my own medical record with the help of AI tools. The cytogenetics section of my bone marrow biopsy listed a translocation I had never heard of: t(11;14). A piece of chromosome 11 had swapped places with a piece of chromosome 14, placing a growth-promoting gene called cyclin D1 under a powerful genetic switch that normally drives antibody production. My cancer cells became disproportionately dependent on a survival protein called BCL-2, the molecule that tells a cell "do not die."

The translocation was a checkpoint failure. But it also created a regulatory context that never should have existed—a growth gene lashed to an antibody accelerator. The dependency it created was the vulnerability my treatment would eventually target.

You do not feel these systems eroding. Weeks before the emergency room, a routine lab panel had come back with a flag: hypogammaglobulinemia, abnormally low immunoglobulin levels. The lab note explicitly recommended a plasma cell workup. That note sat in the system. Nobody ordered the workup. Nobody called. By the time I reached the ER, the clone had been depositing toxic proteins into my heart for months. The signal that something was wrong had been there. The system that should have acted on it did not.

How the Body Keeps Order

Mutations are constant. Normal tissue can carry many driver-like mutations, sometimes reaching burdens seen in some tumors, without forming cancer. The body is managing mutations right now. The question is how.

The body's defenses operate in three layers, each catching what the previous one missed.

Layer 1 is internal checkpoints. Every cell carries its own damage inspector: p53. When a cell accumulates DNA damage, p53 evaluates the severity. Minor damage gets repaired. Severe damage triggers apoptosis. When p53 loses function, damaged cells no longer halt division.

Layer 2 is tissue constraints. Even a cell that has lost its internal brakes faces physical barriers. Contact inhibition stops neighboring cells from overcrowding. Terminal differentiation locks cells into specialized roles. The physical architecture of tissues keeps cells in their designated locations.

Layer 3 is immune surveillance. Natural killer cells and cytotoxic T cells continuously scan for aberrant surface proteins. When they find a cell displaying the wrong molecular markers, they kill it. This is the most adaptive layer.

Cancer emerges not when one layer fails but when a lineage escapes enough layers to begin adapting for its own survival rather than the organism's.

Cellular Cooperation and Defection

Athena Aktipis framed the problem as cellular cheating: every multicellular organism is a society of cells that have agreed to cooperate, and cancer is what happens when some cells stop holding up their end of the deal. The policing problem is visible even in the simplest multicellular organisms. Dictyostelium discoideum, the social amoeba, aggregates into a multicellular slug when food runs scarce. Cheater lineages arise that dodge the stalk. Cooperation requires enforcement, enforcement is costly, and any enforcement system can be defeated by a defector that finds the gap.

How Evolution Solved Peto's Paradox

The elephant story illustrates Layer 1 reinforcement. Joshua Schiffman's team found that the elephant genome contains at least twenty TP53 copies, including one canonical gene and nineteen retrogene copies. Humans carry one gene with two copies.

When researchers placed elephant blood cells and human blood cells side by side and hit them with identical doses of ionizing radiation, elephant lymphocytes were roughly twice as likely to execute apoptosis as human lymphocytes at equivalent radiation doses. The human cells were attempting repair. The elephant cells were choosing to die rather than risk survival with damaged DNA.

More copies of the damage sensor. A lower tolerance for risk. Cells that die rather than gamble on repair. That is what twenty copies of a damage sensor buys.

Naked mole rats live over thirty years with extremely low rates of spontaneous neoplasms. Their primary defense: high-molecular-mass hyaluronan enforces contact inhibition so stringent that cells cannot crowd together even if they try. This is Layer 2 reinforcement. Bowhead whales, which can live over two hundred years, show duplications in genes associated with DNA repair and cell-cycle regulation—potentially making fewer mistakes to begin with. Layer 1 reinforcement at the source.

Different mechanisms, same logic: constrain early, constrain continuously, do not wait for a problem to become visible before responding.

What Breaks in Humans

By the time a blood cancer becomes detectable through standard labs, or a solid tumor becomes visible on imaging, Layer 1 checkpoints have already failed, the clone has already adapted, and the evolutionary landscape is already complex. In my case, the upstream signal was already there. The hypogammaglobulinemia flag was not a tumor marker. It was a sign that something had gone wrong in my immune cell populations. Instead, it was filed and forgotten.

Earlier detection alone is not enough. Earlier detection must be paired with the clinical wisdom to know when and how to act. A therapy that shrinks a tumor by 90 percent has real value. But if it selects for a resistant clone that dominates the remaining 10 percent, it has not solved the problem. It has changed the problem into something harder.

Robert Gatenby and colleagues at the Moffitt Cancer Center tested adaptive therapy directly in human trials. Instead of administering the maximum tolerated dose of abiraterone continuously until the cancer progressed, they adjusted doses based on PSA response. Under standard continuous dosing, resistance to abiraterone typically emerges at a median of roughly 16.5 months. In the adaptive therapy pilot, several patients maintained response far longer than the standard median. The approach treated the cancer not as an enemy to be eradicated but as a population to be managed, its evolutionary dynamics steered rather than ignored.

Coming Back to the Paradox

An elephant cell and a human cell receive the same dose of radiation. Under the microscope, the elephant cell executes apoptosis. The human cell enters repair. That difference, replicated across thousands of cells in a dish, across millions of years of evolutionary time, is the difference between a system that absorbs damage and one that eventually breaks under it.

I cannot add nineteen copies of TP53 to my genome. But I can understand which layer failed in my case. The most useful thing I did after diagnosis was ask for the cytogenetics and molecular profile of my specific disease. That shifted the questions I could ask. Which checkpoint failed (Layer 1)? What does the microenvironment mean for resistance (Layer 2)? What immune-escape features matter (Layer 3)?

Understanding which layer failed, what vulnerability it created, and how treatment exploits it did not come from my oncologist's initial protocol. It came from asking for the cytogenetics, learning about my own disease, and becoming my own advocate.

---

Steve Brown is the CEO and co-founder of CureWise, an AI company helping patients become informed advocates by understanding their lab results, genomic profiles, and treatment options. This post reflects his personal experience and is not medical advice.